• Explore /
  • Poster
  • / A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).

A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).

Abstract Poster

Authors

null

Karen W. L. Yee

Princess Margaret Cancer Center, Toronto, ON, Canada

Karen W. L. Yee , Michael Savona , Morten Sorensen , Peter Brown , William G. Blum , Daniel J. DeAngelo , Martin Gutierrez , Ramiro Garzon , Andre C. Schuh , Nashat Y. Gabrail , Martha Wadleigh , Jeffrey E. Lancet , Bijal D. Shah , Jesus G. Berdeja , Nina D. Wagner-Johnston , Ian Flinn , Tami Rashal , Michael Kauffman , Sharon Shacham , Richard M. Stone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01607892

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 7032)

DOI

10.1200/jco.2014.32.15_suppl.7032

Abstract #

7032

Poster Bd #

24

Abstract Disclosures

Similar Posters

First Author: David Shao Peng Tan

First Author: Ulrik Niels Lassen

First Author: John Martignetti

First Author: Morten Mau-Soerensen